Baijin Life Science Holdings Limited
1466.HK
Hong Kong Stock Exchange1.14
HKD
+0.02
- -
Baijin Life Science Holdings Limited
1466.HK
(Hong Kong Stock Exchange)
Recent
price
1.14
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Baijin Life Science Holdings Limited Baijin Life Science Holdings Limited (1466.HK ), an investment holding company incorporated in 2014 and headquartered in Wan Chai, Hong Kong, engages in the purchase, processing, design, production, and wholesale distribution of pearls and jewelry products, including precious stones, metals, costume jewelry, watches, clocks, and silverware. The company operates through five primary segments: Sales of Pearls and Jewellery Products, involving the design, production, and sale of pearls and fine jewelry on an ODM and OEM basis; Skincare Solutions, offering products under the FO brand name to cosmetics stores, hospitals via sales contracts, and individuals through online platforms; Research and Development Services, providing scientific, pharmaceutical, cellular drugs, large molecule drugs, and clinical research services; Brand Marketing and Consulting Services, delivering contract-based marketing and consultation; and Strategic Investment and Financial Services, focusing on real estate financial assets investments. It serves luxury goods, life sciences, and skincare markets, targeting wholesale distributors, retailers, cosmetics outlets, hospitals, online consumers, and investment counterparties, with geographic operations spanning Hong Kong, the People's Republic of China, the United States, Europe, Asia, the United Kingdom, and Japan. In a significant strategic shift, the company, formerly known as Affluent Partners Holdings Limited, underwent a rebranding to Baijin Life Science Holdings Limited in January 2025 to align with its evolving focus on life sciences alongside its jewelry heritage, effective early that year without impacting shareholder rights. This name change reflects a pivot toward expanded R&D in cellular technology-based services, skincare brand development, and diversified operations beyond traditional pearls and jewelry. Recent financial developments include a positive profit alert for the six months ending September 30, 2025, anticipating a net profit of approximately HK$2.5 million versus a prior loss, alongside revenue growth reported in annual results despite a minor loss; however, it recognized a HK$20 million goodwill impairment tied to the acquisition of Tonnett Julis Holdings Limited, and applied to resume share trading on July 28, 2025, with its 2025 AGM scheduled for September 30, 2025.